Summary: A randomized, double-blind, placebo-controlled clinical trial found that switching from combustible cigarettes to a pod-based salt-nicotine electronic cigarette markedly increased short-term quit rates and substantially lowered exposure to several tobacco-related toxicants.
In this trial, daily smokers who switched to a 5% nicotine pod-based e-cigarette were about three times more likely to stop smoking completely within six weeks than those randomized to an identical, nicotine-free device. The study offers timely, real-world evidence for public health decision-makers weighing safer, non-combustible alternatives for smokers who have not quit with standard medications.
Key Facts
- Three-fold higher quit rate: At six weeks, 36.5% of participants using the 5% nicotine pod device reported complete cigarette abstinence versus 11.5% in the zero-nicotine placebo group. This difference persisted at a 10-week follow-up.
- Reduced carcinogen exposure: Both groups showed decreases in several tobacco-related toxicants, particularly NNAL, a lung-selective carcinogen that derives only from tobacco leaf. The 5% nicotine group experienced the largest reductions.
- Nicotine salt delivery matters: Modern pod-based systems use nicotine salt formulations that deliver nicotine more smoothly and efficiently than older vapor designs, better suppressing withdrawal and cravings and making the transition away from cigarettes easier.
- First U.S. randomized placebo-controlled trial for pod-based devices: According to the investigators, this is the first randomized, double-blind, placebo-controlled U.S. trial to evaluate both chemical biomarkers and behavioral outcomes when smokers switch completely from combustible cigarettes to a pod-based salt-nicotine e-cigarette.
- Combustion drives harm: The findings reinforce the public health distinction between nicotine and the harms of smoking: nicotine causes addiction, but the primary drivers of cancer and cardiovascular disease are the toxic byproducts of burning tobacco.
Source: Penn State
Background
Cigarette smoking remains the leading preventable cause of death in the United States, even as prevalence has declined. Electronic cigarettes (e-cigarettes) have evolved rapidly; many earlier studies suggested e-cigarettes expose users to fewer tobacco-specific toxicants and may help some people quit. However, the product landscape has changed, and fresh evidence is needed to evaluate newer pod-based, nicotine-salt devices.
Published in JAMA Network Open, the trial enrolled adults who smoked more than four cigarettes per day and who were interested in switching completely to an e-cigarette. Participants were randomly assigned, under double-blind conditions, to receive either a pod-based device with 5% nicotine or the identical-appearing device with 0% nicotine for six weeks. The zero-nicotine device served as a placebo, preserving the look, feel, vapor, and hand-to-mouth behavior of smoking without biological nicotine replacement.
Investigators collected urine and breath samples at baseline, three weeks, and six weeks to measure biomarkers of exposure to toxicants linked to respiratory, cardiovascular, and cancer risks. The primary biomarker was NNAL, a tobacco-specific metabolite that indicates exposure to a potent lung carcinogen found only in tobacco leaf. Secondary measures included exhaled carbon monoxide, cotinine, cigarettes per day, and volatile organic compound biomarkers.
Of the 104 randomized participants (52 per group), 69 completed the six-week trial. Dropout rates were consistent with prior cessation studies, as participants who failed to quit often discontinue follow-up. At six weeks, the 5% nicotine group showed a higher rate of complete cigarette abstinence (36.5% vs. 11.5%) and higher cotinine levels, indicating use of the nicotine device. Both groups reduced biomarkers of toxicant exposure compared with baseline, and certain biomarkers—such as those for acrylonitrile and acrolein exposure—were significantly lower in the 5% nicotine group.
Although the decrease in NNAL did not reach statistical significance after adjusting for baseline variables, the larger reduction in the 5% nicotine cohort and the substantially higher quit rate suggest the nicotine-delivering device helped many participants stop smoking and reduce exposure to tobacco-specific toxicants.
Interpretation
The trial indicates that electronic cigarettes that deliver nicotine in a manner closer to cigarettes can substantially ease withdrawal and cravings, improving short-term quit rates while lowering exposure to several harmful combustion-related chemicals. These findings support the potential role of pod-based nicotine e-cigarettes as a harm-reduction option for smokers who have not succeeded with standard cessation medications.
Key Questions Answered
Q: If vaping still exposes people to chemicals, how does it help public health?
A: Harm reduction is the guiding principle. Eliminating combustion removes many of the most harmful chemical byproducts of smoking. While quitting all nicotine and tobacco products is ideal, for smokers who cannot quit, switching to a non-combustible nicotine source can substantially reduce exposure to cancer-causing and cardiovascular toxicants.
Q: Why did the zero-nicotine e-cigarette group have lower quit rates?
A: The zero-nicotine device served as a behavioral placebo but provided no biological nicotine replacement. Without nicotine to alleviate withdrawal and cravings, most participants found it harder to quit cigarettes.
Q: What distinguishes modern pod-based e-cigarettes from earlier models?
A: Pod-based devices commonly use nicotine salt formulations that deliver nicotine more smoothly and efficiently than earlier freebase nicotine e-cigarettes. That improved delivery better suppresses cravings and can make complete switching away from combustible cigarettes more achievable for some smokers.
Editorial Notes
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by editorial staff.
About this nicotine and addiction research news
Author: Christine Yu
Source: Penn State
Contact: Christine Yu – Penn State
Image: Credit to Neuroscience News
Original Research: “Toxicant Exposures After Switching From Cigarettes to a Pod-Based Electronic Cigarette” by Jessica M. Yingst and colleagues. JAMA Network Open. DOI: 10.1001/jamanetworkopen.2026.13292. (Open access)
Abstract (condensed)
Importance: E-cigarettes generally expose users to fewer tobacco-related toxicants than combustible cigarettes. Pod-based nicotine-salt devices have become widespread, and evidence is needed on their impacts among people who smoke.
Objective: To compare short-term toxicant exposure and smoking behavior after switching from cigarettes to a pod-based 5% nicotine e-cigarette versus a 0% nicotine device.
Design, setting, and participants: This double-blind, randomized, placebo-controlled trial enrolled adults who smoked more than four cigarettes per day and wanted to switch completely to an e-cigarette. The study took place at a single academic medical center and included follow-up at six and ten weeks.
Interventions: Participants were randomized 1:1 to a standardized research e-cigarette containing 5% nicotine or 0% nicotine for six weeks.
Main outcomes: The primary outcome was urine NNAL at six weeks. Secondary outcomes included exhaled carbon monoxide, cotinine, cigarettes per day, verified cigarette abstinence, and volatile organic compound biomarkers.
Results: Among 104 randomized participants, the 5% nicotine group had a significantly higher proportion of cigarette abstinence at six weeks (36.5% vs. 11.5%). The 5% group also showed lower levels of certain biomarkers of carcinogen and cardiac toxicant exposure. While the primary NNAL difference did not reach conventional statistical significance after adjustment, overall toxicant exposures declined in both groups compared with baseline.
Conclusions: Switching from cigarettes to a nicotine-delivering pod-based e-cigarette reduced exposure to some harmful tobacco-related chemicals and increased short-term smoking cessation rates. E-cigarettes that deliver nicotine similarly to cigarettes may play a role in reducing harms caused by combustible tobacco.
Trial registration: ClinicalTrials.gov Identifier: NCT03625986
Funding: Supported by the National Institute on Drug Abuse, the National Center for Advancing Translational Sciences, the National Cancer Institute, and the U.S. Food and Drug Administration.
Principal investigators and contributors: Jonathan Foulds (principal investigator) and coauthors from Penn State College of Medicine, including Jessica Yingst, Sophia Allen, Zachary Bitzer, Junjia Zhu, Christopher Sciamanna, and other research staff and trainees who contributed to study design, data collection, and analysis.